An audacious real estate project costing just over 41 million euros and financed under the CPER by Occitanie Pyrénées-Méditerranée Region, Toulouse-Métropole, the State, Inserm, CNRS, FNADT and FEDER, the building, owned by Inserm, houses the CRCT’s teams and platforms, as well as the CREFRE’s services (Regional Centre for Functional Exploration and Experimental Resources, UMS 006 Inserm/University of Toulouse III Paul Sabatier/ENVT), on more than 13,000 m2 of usable space (25,000 m2 of total surface area). It was inaugurated by the Prime Minister in October 2014.
Discover the architectural project of our building on the VIB Architecture website by clicking here.
Gilles Favre is Professor of Biochemistry and Medical Biology at the University of Toulouse; he is also Scientific Director and Director of the Medical Oncology Biology Laboratory at the Toulouse-Oncopole University Cancer Institute.
Lastly, Gilles Favre is also in charge of the SIGNATHER team at the CRCT. Gilles Favre’s research focuses on cell signalling in cancer, identification of therapeutic targets and translational research approaches for the discovery of new biomarkers. He has made major contributions to…
Internal rules and regulations
The internal regulations determine the operating procedures of the Toulouse Cancer Research Centre (UMR1037) and aim to define the organisation and rules of governance and management.
Any modification of these internal regulations must be proposed by the Director of the CRCT and validated by the Laboratory Council of the Unit.